Breaking World Pharma News

Abbott and Google launch first-of-its-kind partnership to transform everyday health through glucose insights and AI

Tue, 11 Aug 2026 10:00:00 +0200

Abbott (NYSE: ABT) today announced a first-of-its-kind partnership with Google Health to redefine how people understand and manage their health. By combining glucose insights from Abbott's Lingo biowearable with Google's expertise in artificial intelligence (AI) and consumer technology, the multi-year collaboration makes personalized metabolic insights more actionable, helping people take a more proactive approach to their health.

New approach to the development of non-opioid painkillers

Mon, 10 Aug 2026 10:00:00 +0200

An international research team led by the Medical University of Vienna has investigated a new peptide derived from cone snail venom which significantly reduced inflammation-induced pain in an animal model. Crucially, its effect takes hold immediately after subcutaneous injection, whereas previously known cone snail peptides must be administered directly into the cerebrospinal fluid.

More than half of U.S. adults now eligible for statins under new guidelines

Fri, 07 Aug 2026 10:00:00 +0200

More than half of U.S. adults ages 30 to 79 - about 87.5 million people - are now recommended for statins to prevent cardiovascular disease under newly updated clinical guidelines, according to a study by University of Pittsburgh School of Medicine researchers published in JAMA.

The new recommendations significantly change how doctors assess cardiovascular risk by looking beyond the next 10 years to a person’s risk over several decades.

Many countries overusing powerful antibiotics

Thu, 06 Aug 2026 10:00:00 +0200

Many countries are using too many powerful and inappropriate antibiotics, fuelling antibiotic resistance concerns, while millions lack access to the specific drugs they need. That is according to a major international study of antibiotic use published in The Lancet Public Health.

Research led by City St George's, University of London and University of Oxford developed the first global framework that estimates how many and which type of antibiotics each country needs to treat their infections.

GLP-1 diabetes drugs linked to increased risk of hair loss

Wed, 05 Aug 2026 10:00:00 +0200

Use of glucagon-like peptide-1 (GLP-1) receptor agonists used to treat type 2 diabetes and obesity are associated with an increased risk of hair loss (alopecia) in adults with type 2 diabetes, finds a study published by The BMJ.

Although the absolute risk is low, awareness of this potential effect may help to inform shared treatment decisions, say the researchers.

Study reveals structure of brain protein and identifies potential drug target for epilepsy research

Tue, 04 Aug 2026 10:00:00 +0200

Scientists at the Icahn School of Medicine at Mount Sinai have uncovered the first high-resolution structure of NBCn2, a brain protein linked to epilepsy, autism spectrum disorder, and other neurological conditions, and developed the first compounds capable of inhibiting its activity. The findings provide a new framework for studying how altered brain signaling contributes to disease and may help advance future therapeutic research.

A secret weapon against superbugs

Mon, 03 Aug 2026 10:00:00 +0200

Antibiotic resistance has quietly become one of the greatest threats to global healthcare. Each year, drug-resistant bacteria claim lives by rendering once-reliable antibiotics ineffective, turning routine surgeries, cancer treatments, and even common infections into potentially life-threatening events.

Scientists around the world are racing to find new ways to stay ahead of these evolving pathogens. The answer may not lie in discovering an entirely new antibiotic, but in reinventing the chemistry behind the ones we already have.

Researchers clear two major hurdles for minimally invasive cancer therapy

Fri, 31 Jul 2026 10:00:00 +0200

In a promising development for cancer treatment, a collaborative research team has overcome two issues that have prevented photo thermal therapy, a much less invasive treatment option than surgery and/or radiation, from becoming more common.

Photothermal therapy uses near-infrared laser light to selectively heat and destroy cancer cells. However, when the immune system senses the nanoparticles carrying therapeutic agents it often begins clearing them before they can reach the tumors.

AI platform could speed peptide drug discovery

Thu, 30 Jul 2026 10:00:00 +0200

Penn Engineers have developed PeptiVerse, an AI-powered platform that predicts key chemical and biological properties of peptides, the strings of amino acids whose medical potential has been demonstrated by the success of GLP-1 drugs, the widely used weight-loss treatments.

In Nature Communications, the researchers describe how they trained PeptiVerse using a wide range of data sets, allowing it to predict properties that can help determine whether a peptide is worth pursuing as a potential drug,

Starving bacteria to death

Wed, 29 Jul 2026 10:00:00 +0200

Like all living cells, bacteria need vitamins to survive and cause infection. Unlike humans, many bacteria rely on specialized membrane transporters - called energy-coupling factor transporters, or ECF transporters - to actively and efficiently import vitamins from their surroundings into the cell. Block these transporters, and the bacteria run out of essential nutrients and die. What makes ECF transporters particularly attractive as a drug target is that human cells do not have them.

Cutting-edge drug shows promise for patients with NRAS-driven melanoma

Tue, 28 Jul 2026 10:00:00 +0200

A research team from Huntsman Cancer Institute at the University of Utah (the U) reports that a groundbreaking pathway-targeted therapy could be an effective treatment for certain melanoma patients and fill an unmet clinical need for patients with advanced disease.

Martin McMahon, PhD, senior director of preclinical translation at Huntsman Cancer Institute and professor of dermatology at the U, evaluated an investigative compound of the drug daraxonrasib in NRAS-driven melanoma.

Development of a novel "degraders" for the selective elimination of cancer cells

Mon, 27 Jul 2026 10:00:00 +0200

Researchers from two Technion faculties have jointly developed a new compound and demonstrated its effectiveness against aggressive tumor cells.

A study published in Oncogene presents an innovative strategy for the particularly complex medical challenge of destroying aggressive, treatment-resistant tumors.

RAS inhibitor daraxonrasib demonstrates initial anti-tumor activity in pancreatic cancer

Fri, 24 Jul 2026 10:00:00 +0200

The targeted RAS inhibitor therapy daraxonrasib demonstrated the potential to improve patient outcomes over current standard treatments for patients with RAS-mutant pancreatic cancer, according to results of a Phase 1/2 trial led by researchers at The University of Texas MD Anderson Cancer Center.

The study, published in The New England Journal of Medicine, was led by David Hong, M.D., deputy chair of Investigational Cancer Therapeutics.

OPTAR opens a new route to first-in-class drug targets

Thu, 23 Jul 2026 10:00:00 +0200

A research team has developed OPTAR, a computational tool for discovering novel therapeutic targets from large-scale omics data. Designed to identify proteins without known drugs or prior disease links, OPTAR integrates literature mining, protein-protein interaction-based disease inference, and binding-pocket assessment. Using hepatocellular carcinoma (HCC) as a test case, the tool prioritized UBE2J1, KDELR3, and VTI1A as functional targets, offering a practical route from complex omics datasets to first-in-class drug discovery.

Cutting-edge drug shows promise for patients with NRAS-driven melanoma

Wed, 22 Jul 2026 10:00:00 +0200

GLP-1 shows promise for patients with advanced fatty liver disease

Tue, 21 Jul 2026 10:00:00 +0200

Researchers at University of California San Diego School of Medicine have reported results from a large international clinical trial showing that semaglutide, a medication in the GLP-1 class of drugs widely used to treat diabetes and obesity, may help reduce liver scarring in patients with advanced fatty liver disease, including those with early-stage cirrhosis.

The study results, published in the online edition of The Lancet Gastroenterology & Hepatology, address a major unmet need for people with metabolic dysfunction-associated steatohepatitis (MASH),

A deep dive into drug delivery

Mon, 20 Jul 2026 10:00:00 +0200

Modern medicine increasingly relies on targeted drug delivery, a process during which therapeutic molecules are transported directly to specific organs or even certain cell types. To do this, drugs are often packaged inside biocompatible particles (nanoparticles), commonly composed of different fat molecules.

The efficiency of the delivery process is determined by many characteristics of the particles.

Researchers create new path to target hard-to-drug prostate cancer protein

Fri, 17 Jul 2026 10:00:00 +0200

In the United States, prostate cancer is a leading cause of cancer-related disease and death in men.

About half of prostate cancer cases in patients of European ancestry have a gene rearrangement where the genes TMPRSS2 and ERG are fused together. This causes the ERG protein to be turned on, increasing the growth and migration of tumor cells.

Could an investigational drug that targets DNA damage help treat Alzheimer's disease?

Thu, 16 Jul 2026 10:00:00 +0200

Accumulation of DNA damage in the brain’s neurons may contribute to the development of Alzheimer’s disease. New research in FEBS Open Bio demonstrates the therapeutic potential of a drug that targets this process.

Using a mouse model of Alzheimer’s disease, investigators found that treatment with KCL-286, a molecule that activates the retinoic acid receptor-β (RARβ), enhanced the repair of DNA damage in neurons.

Novel antibody-drug conjugate eliminates residual cancer cells in majority of patients with B-cell ALL

Wed, 15 Jul 2026 10:00:00 +0200

Researchers at The University of Texas MD Anderson Cancer Center were able to eradicate measurable residual disease (MRD) in B-cell acute lymphoblastic leukemia (ALL) patients, a critical step in improving long-term survival outcomes, by treating with the antibody-drug conjugate (ADC) inotuzumab ozogamicin.

Results from the Phase 2 study were published in Blood Cancer Journal. Among 37 patients treated, 70% achieved MRD negativity, including strong responses in both Philadelphia chromosome-positive and -negative disease.